Saxagliptin/metformin extended release

Drug Profile

Saxagliptin/metformin extended release

Alternative Names: Kombiglyze XR; Metformin extended release/saxagliptin; Metformin XR/saxagliptin; Onglyza/metformin XR FDC; Saxagliptin/metformin XR

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; BC Women's Hospital & Health Centre
  • Class Adamantanes; Antihyperglycaemics; Biguanides; Cycloparaffins; Dipeptides; Insulin sensitisers; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Prediabetic-state

Most Recent Events

  • 11 Jul 2017 Saxagliptin/metformin extended release is still in Preregistration for Type-2 diabetes mellitus in China (AstraZeneca pipeline, July 2017)
  • 01 Oct 2016 AstraZeneca completes a phase-III clinical trial in Prediabetic state (impaired glucose regulation in patients with polycystic ovary syndrome) in USA (PO)
  • 10 Feb 2014 AstraZeneca acquires oral fixed-dose combination tablet of saxagliptin and extended-release metformin from Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top